Chlamydia pneumoniae-specific humoral immune responses and clinical disease parameters in multiple sclerosis

Humoral immune responses to Chlamydia pneumoniae (C. pneumoniae) were studied in paired sera and cerebrospinal fluid (CSF) of patients with definite multiple sclerosis (MS) and other inflammatory and non-inflammatory neurological diseases. Seropositivity was not significantly different between these groups. However, C. pneumoniae-specific IgG titers were significantly higher in CSF of MS than in controls. Sixteen out of 52 seropositive MS patients (30.8%) showed intrathecal synthesis of C. pneumoniae-specific IgG but only one of 43 seropositive controls (2.3%). In MS, this was strongly associated with intrathecal synthesis of polyclonal IgG in 13/16 patients. However, these elevated C. pneumoniae antibody titers in CSF did not significantly correlate with disease duration, disease course, clinical or MRI disease activity, disability or presence of oligoclonal IgG in MS.

Download Full-text

Analysis of humoral immune responses to recombinant Chlamydia pneumoniae antigens

International Journal of Infectious Diseases ◽

10.1016/j.ijid.2019.12.007 ◽

2020 ◽

Vol 91 ◽

pp. 232-239

Author(s):

Jürgen Benjamin Hagemann ◽

Ulrike Simnacher ◽

Miriam Theresia Marschall ◽

Julia Maile ◽

Erwin Soutschek ◽

...

Keyword(s):

Immune Responses ◽

Chlamydia Pneumoniae ◽

Humoral Immune ◽

Humoral Immune Responses

Download Full-text

Cellular and Humoral Immune Responses Against Autoreactive T cells in Multiple Sclerosis Patients After T cell Vaccination

Journal of Autoimmunity ◽

10.1006/jaut.1999.0314 ◽

1999 ◽

Vol 13 (2) ◽

pp. 233-246 ◽

Cited By ~ 23

Author(s):

Guy Hermans ◽

Ulrike Denzer ◽

Ansgar Lohse ◽

Jef Raus ◽

Piet Stinissen

Keyword(s):

Multiple Sclerosis ◽

T Cells ◽

T Cell ◽

Immune Responses ◽

Autoreactive T Cells ◽

Humoral Immune ◽

Humoral Immune Responses ◽

T Cell Vaccination ◽

Multiple Sclerosis Patients

Download Full-text

EBV-specific immune responses in patients with multiple sclerosis responding to IFNβ therapy

Multiple Sclerosis Journal ◽

10.1177/1352458511426816 ◽

2011 ◽

Vol 18 (5) ◽

pp. 605-609 ◽

Cited By ~ 12

Author(s):

Manuel Comabella ◽

Kristina Kakalacheva ◽

Jordi Río ◽

Christian Münz ◽

Xavier Montalban ◽

...

Keyword(s):

Multiple Sclerosis ◽

T Cell ◽

Immune Responses ◽

T Cell Responses ◽

Lytic Replication ◽

Nuclear Antigen ◽

Humoral Immune ◽

Cell Responses ◽

Humoral Immune Responses ◽

Specific Igg

Background: Symptomatic primary infection with the human γ-herpesvirus Epstein–Barr virus (EBV) and elevated immune responses to EBV are associated with the development and progression of multiple sclerosis (MS). Interferon-beta (IFNβ), first-line treatment for relapse-onset MS, exhibits complex immunoregulatory and antiviral activities. Objective: To determine EBV-specific immune responses in patients with MS during IFNβ therapy. Methods: We evaluated cellular and humoral immune responses to EBV- and human cytomegalovirus (HCMV)-encoded antigens in patients with MS before and 1 year after IFNβ treatment by ELISA and flow cytometry. Twenty-eight patients with MS who showed a clinical response to IFNβ as defined by the absence of relapses and lack of progression on the Expanded Disability Status Scale score during the first 2 years of treatment were included. Results: Clinically effective IFNβ-therapy was associated with a downregulation of proliferative T cell responses to the latent EBV nuclear antigen-1 (EBNA1). EBNA1-specific IgG responses as well as cellular and humoral immune responses to MHC class I restricted EBV antigens expressed during lytic replication and viral B cell transformation were similar before and after IFNβ therapy. Although HCMV-specific IgG levels slightly decreased, proliferative T-cell responses towards HCMV antigens remained unchanged during IFNβ therapy. Conclusion: Clinically effective IFNβ therapy is associated with a reduction of proliferative T-cell responses to EBNA1.

Download Full-text